Latest HER2/neu Stories
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc.
MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A.
HER3-positive circulating tumor cells home in on omentum; new target to thwart metastasis
ROCKVILLE, Md., July 2, 2014 /PRNewswire/ -- A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with
- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill.,
NEW YORK, June 17, 2014 /PRNewswire/ -- According to GLOBOCAN 2012, breast cancer was the second most commonly diagnosed form of cancer in 2012 with 1.7 million new cases, and accounting
DUBLIN, June 16, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bqwbck/companion) has announced the addition of the "Companion Diagnostics
ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted
OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.